Biopharmaceutical company ValenzaBio recently completed a $70 million Series A financing round led by Fidelity Management and Research Company and Surveyor Capital. ValenzaBio plans to use the new financing to advance pipeline programs into autoantibody-mediated diseases, thyroid eye disease, inflammatory disorders and other therapeutic areas.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,